VIS 267
Alternative Names: VIS-267Latest Information Update: 09 Oct 2022
At a glance
- Originator Visterra
- Class
- Mechanism of Action Complement C3-C5 convertases modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders
Most Recent Events
- 27 Sep 2022 Preclinical trials in Autoimmune disorders in USA (Parenteral) (Visterra website, September 2022)